Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41467   clinical trials with a EudraCT protocol, of which   6815   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-024423-24
    Sponsor's Protocol Code Number:AB10015
    National Competent Authority:Ireland - HPRA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-11-06
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedIreland - HPRA
    A.2EudraCT number2010-024423-24
    A.3Full title of the trial
    A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A controlled clinical study to investigate the effectiveness and safety of the medicine called masitinib when used together with a currently available medicine Riluzole when treating the illness called Amyotrophic Lateral Sclerosis (ALS)
    A.3.2Name or abbreviated title of the trial where available
    IRELAND Phase 2/3 study comparing Masitinib/Placebo in ALS
    A.4.1Sponsor's protocol code numberAB10015
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAB Science
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAB Science
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAB Science
    B.5.2Functional name of contact pointClinical Study Manager (V Arnold)
    B.5.3 Address:
    B.5.3.1Street AddressAB Science, 3 Avenue George V
    B.5.3.2Town/ cityParis
    B.5.3.3Post code75008
    B.5.3.4CountryFrance
    B.5.4Telephone number +33 147 20 30 08
    B.5.5Fax number +33 147 20 24 11
    B.5.6E-mailvincent.arnold@ab-science.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMasitinib 100 mg Tablets
    D.3.2Product code AB1010
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMasitinib mesylate
    D.3.9.1CAS number 790-299-79-5
    D.3.9.2Current sponsor codeAB1010
    D.3.9.3Other descriptive nameSUB126308
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMasitinib 200 mg Tablets
    D.3.2Product code AB1010
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMasitinib mesylate
    D.3.9.1CAS number 790-299-79-5
    D.3.9.2Current sponsor codeAB1010
    D.3.9.3Other descriptive nameSUB126308
    D.3.9.4EV Substance CodeAS3
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Amyotrophic lateral Sclerosis
    E.1.1.1Medical condition in easily understood language
    A rare disorder of nerve cells (motor neurone disease) located in the brain and connected tissue. ALS causes the nerve cells to die and stops messages being sent to the muscles in the body.
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level PT
    E.1.2Classification code 10028003
    E.1.2Term Motor neurone disease
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level PT
    E.1.2Classification code 10002026
    E.1.2Term Amyotrophic lateral sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the Efficacy and safety of the study drug (Masitinib) as add-on therapy in combination with the drug Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis(ALS). Riluzole is currently the only approved drug for the treatment of ALS.
    The primary endpoint for this study is the comparison of the Revised ALS Functional Rating Scale (ALSFRS -revised) from baseline to week 48. ALSFRS-revised is a validated rating system for monitoring the progression of disability in ALS patients.

    Extension period:
    Given that a favourable benefice/risk balance has been documented and approved, the objective of the extension phase is to evaluate the maintenance of the clinical benefit of patients at each extension visit through the same efficacy and safety measures implemented from baseline to week 48.
    E.2.2Secondary objectives of the trial
    - Combined Assessment of Function and Survival (CAFS)
    - Survival defined as the time from randomisation to the date of documented death or first tracheotomy
    - Time to first tracheotomy defined as the time from randomisation to the time of the first tracheotomy
    - Change of Forced Vital Capacity (FVC) from baseline to each time point (week 4, 8, 12, 24, 36, 48 and at each patient visit from the date of entry in the extension period).
    - Number of failure defined as a 9-point drop in ALSFRS-R or death from baseline
    - Change from baseline to each time point (week 4, 8, 12, 24, 36 and at each patient visit from the date of entry in the extension period) in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised
    - Survival rate defined as the rate of patients alive without tracheotomy at each time point (week 12, 24, 36, 48 and at each patient visit from the date of entry in the extension period)
    - Change in cystatin C level from baseline to each time point
    - Time to fi
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    The protocol allows for an 2 optional studies.

    - A pharmacogenomic sub-study in order to define efficacy or safety genomic predictive criteria, a blood sample will be collected if a patient experiences either severe skin toxicity or severe neutropenia. The objectives of this genomic study are to evaluate potential relationships between the genes, efficacy and safety of the study treatment. Participation to this additional study will require additional blood samples and a separate consent will be required.

    - pharmacokinetic sub-study, Additional blood samples will be collected at week 0 and week 1 to investigate the pharmacokinetic profile of Riluzole used in conjunction with Masitinib. Participation to this additional study will require additional blood samples and a separate consent will be required.
    E.3Principal inclusion criteria
    1.Female or male patient aged between 18 and 75 years of age, with a weight > 50 kg and BMI (body mass index) between 18 and 35 kg/m².
    2. Familial or sporadic ALS
    3. Patient diagnosed with laboratory supported, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (Brooks, 1994)
    4. Disease duration from symptoms onset no longer than 36 months at the screening visit
    5. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening
    6. Patient with a FVC (Forced Vital Capacity) equal to or more than 60% predicted normal value for gender, height, and age at the screening visit
    7. Patient with life expectancy ≥ 6 months
    8. Patient with adequate organ function at screening and baseline:
     Absolute Neutrophils Count (ANC) ≥ 2 x 109/L
     Hemoglobin ≥ 10 g/dL
     Platelets (PTL) ≥ 100 x 109/L
     AST/ALT ≤ 3 ULN
     Bilirubin ≤ 1.5 ULN
     Albuminemia > 1 x LLN
     Creatinine clearance > 60 mL/min (Cockcroft and Gault formula)
     Proteinuria < 30 mg/dL (1+) on dipstick; in case of the proteinuria ≥ 1+ on the dipstick, 24 hours proteinuria must be < 1.5g/24 hours
    9. Male and Female patient of childbearing potential (entering the study after a menstrual period and who have a negative pregnancy test), who agrees to use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception (with failure rate < 1%) during the study and for 3 months after the last treatment intake. Acceptable forms of contraception include:
    - combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: 
    o oral
    o intravaginal
    o transferral
    - progestogen-only hormonal contraception associated with inhibition of ovulation:
    o oral
    o inject able hormonal contraception
    o implantable hormonal contraception
    - placement of an intrauterine device (IUD)
    - placement of an intrauterine hormone-releasing system ( IUS)
    - bilateral tubal occlusion
    - vasectomised partner
    - sexual abstinence
    10. Female patient of childbearing potential must have a negative pregnancy test at screening and baseline
    11. Patient able and willing to comply with study procedures as per protocol
    12. Patient able to understand, and willing to sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
    13. Patient able to understand, and willing to follow the safety procedures mentioned on the patient card in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first two months of treatment
    E.4Principal exclusion criteria
    1. Patient with history of hematologic, hepatic, respiratory disorder that is clinically significant for his/her participation in the study
    2. Patient who underwent tracheotomy and /or gastrostomy
    3. Patient with a diagnosis of cancer or evidence of continued disease within five years before starting study treatment
    4. Patient with significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and psychiatric illness
    5. Patient who have participated in a clinical trial within 3 months prior to screening
    6. Pregnant, or nursing female patient
    7. Patient with a known diagnosis of human immunodeficiency virus (HIV) infection
    8. Patient with known active hepatitis B, hepatitis C or tuberculosis
    9. Patient with any severe and/or uncontrolled medical condition
    10. Patient having cardiac disorders defined by at least one of the following conditions:
    *Patient with recent cardiac history (within 6 months) of:
    - Acute coronary syndrome
    - Acute heart failure (class III or IV of the NYHA classification)
    - Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
    * Patient with cardiac failure class III or IV of the NYHA classification
    * Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
    * Syncope without known aetiology within 3 months
    * Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
    11. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent

    PREVIOUS TREATMENTS WASH OUT
    12. Patient treated with any investigational agent within 3 months prior to screening
    E.5 End points
    E.5.1Primary end point(s)
    Compare the efficacy and safety of masitinib combined with Riluzole as add-on therapy versus placebo combined with Riluzole as add-on therapy in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

    Primary Objective is stated as: Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS) - Revised from baseline to week 48.
    E.5.1.1Timepoint(s) of evaluation of this end point
    All data will be analysed at Week 48.

    In addition safety, futility and an interim analysis is planned during the study. An Independent Data Monitoring Committee without direct involvement in the conduct of the study, will monitor safety data throughout the duration of the study to determine if continuation is appropriate both scientifically and ethically.

    Futility analysis:
    The IDMC will review the different efficacy criteria about 48 weeks after the 60-75th patient is randomized.

    Interim analysis:
    An independent statistical center will be responsible for carrying out the planned interim analysis after about 50% of patients are randomised.
    E.5.2Secondary end point(s)
    - Combined Assessment of Function and Survival (CAFS)
    - Survival defined as the time from randomisation to the date of documented death or first tracheotomy
    - Time to first tracheotomy defined as the time from randomisation to the time of the first tracheotomy
    - Change of Forced Vital Capacity (FVC) from baseline to each time point (week 4, 8, 12, 24, 36, 48 and at each patient visit from the date of entry in the extension period)
    - Number of failure defined as a 9-point drop in ALSFRS-R from baseline or death
    - Change from baseline to each time point (week 4, 8, 12, 24, 36, and at each patient visit from the date of entry in the extension period) in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised
    - Survival rate defined as the rate of patients alive without tracheotomy at each time point (week 12, 24, 36, 48, and at each patient visit from the date of entry in the extension period)
    - Change in cystatin C level from baseline to each time point
    - Time to first gastrostomy defined as the time from randomisation to the time of the first gastrostomy
    - Absolute and relative change from baseline in ALSAQ- 40 at each time point
    - Safety: occurrence of Adverse Events (AE), changes on clinical examination including vital signs and weight, ECG and laboratory exams (biochemistry, hematology and urinalysis)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Full analysis will be performed at Week 48

    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Belgium
    Colombia
    France
    Germany
    Greece
    Hungary
    Ireland
    Italy
    Mexico
    Netherlands
    Portugal
    Romania
    Slovakia
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS W48. After W48 the patient may enter the extension if approved by the Investigator, patient, available study data and competent authority. After 96 weeks of exposure patients will need to re-sign consent.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days31
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 331
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 50
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 381
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    If a patient leaves the trial they will be treated according to standard of care.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-10-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA